Watch CTSO. Know when insiders buy.
One email the day a filing lands. Free.
CTSO
Cytosorbents Corp
6.33
+5.98 +1708.57%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
53
WATCH · insiders 58, shorts 48
Insiders, 90 days
+$70K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $397.8MP/E —DIV YIELD —FCF YIELD -2.34%REV TTM —NET INCOME −$18.2MNET DEBT $12.8M52W 0.31 – 6.33SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.6M | +0.2% | 73.2% | −$2.6M | −$4.4M | −326.9% | -0.07 | −$583K | $14K | −$597K | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$3M | −$5.1M | — | -0.08 | −$1.2M | $11K | −$1.2M | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.4M | −$5.5M | — | -0.09 | −$4.8M | $108K | −$4.9M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$2.9M | −$3.2M | — | -0.05 | −$2.6M | $17K | −$2.6M | Nov 13 |
| Q2 2025 · Jun 30 | $9.6M | — | 70.9% | −$3.6M | $1.9M | — | 0.03 | −$1.5M | $37K | −$1.5M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$3.9M | −$1.5M | — | -0.02 | −$3.5M | $2K | −$3.5M | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.4M | −$7.6M | — | -0.14 | −$2.3M | $69K | −$2.4M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$4.8M | −$2.8M | — | -0.05 | −$2.5M | $152K | −$2.6M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$3.6M | −$4.3M | — | -0.08 | −$4.8M | $18K | −$4.8M | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$4.7M | −$6.1M | — | -0.11 | −$4.8M | $45K | −$4.9M | May 14 |
| Q4 2023 · Dec 31 | — | — | — | −$9.4M | −$5.8M | — | -0.12 | −$6.4M | $95K | −$6.5M | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$7.4M | −$9.2M | — | -0.21 | −$5.2M | $142K | −$5.3M | Mar 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$14.7M | −$8.2M | — | -0.13 | −$12.4M | $164K | −$12.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$16.5M | −$20.7M | — | -0.38 | −$14.4M | $284K | −$14.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$31.9M | −$29.2M | — | -0.65 | −$21.7M | $538K | −$22.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$31.5M | −$32.8M | — | -0.75 | −$28.2M | $6.1M | −$34.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$22.7M | −$24.6M | — | -0.57 | −$14M | $3.6M | −$17.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$10.4M | −$7.8M | — | -0.20 | −$5.6M | $708K | −$6.3M | — | — |
Every number comes from Cytosorbents Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.